{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T20:56:25Z","timestamp":1788209785108,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.hoc.2020.06.002","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T08:31:01Z","timestamp":1596011461000},"page":"837-847","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Watch and Wait in Mantle Cell Lymphoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Christina","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.hoc.2020.06.002_bib1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.002_bib2","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","article-title":"Molecular pathogenesis of mantle cell lymphoma","volume":"122","author":"Jares","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"12","key":"10.1016\/j.hoc.2020.06.002_bib3","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1182\/blood-2002-06-1864","article-title":"A\u00a0subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease","volume":"101","author":"Orchard","year":"2003","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2020.06.002_bib4","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3324\/haematol.2010.036277","article-title":"Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis","volume":"96","author":"Ondrejka","year":"2011","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.002_bib5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3324\/haematol.2011.052621","article-title":"In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior","volume":"97","author":"Carvajal-Cuenca","year":"2012","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.hoc.2020.06.002_bib6","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/cncr.27898","article-title":"Using primary site as a predictor of survival in mantle cell lymphoma","volume":"119","author":"Ambinder","year":"2013","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.002_bib7","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A\u00a0new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2020.06.002_bib8","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network","volume":"34","author":"Hoster","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2020.06.002_bib9","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1002\/cncr.31328","article-title":"Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy","volume":"124","author":"Greenwell","year":"2018","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.002_bib10","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1182\/blood.V87.10.4302.bloodjournal87104302","article-title":"p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis","volume":"87","author":"Greiner","year":"1996","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2020.06.002_bib11","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.clml.2018.07.282","article-title":"TP53 mutation and complex karyotype portends a dismal prognosis in patients with mantle cell lymphoma","volume":"18","author":"Obr","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.002_bib12","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.V89.1.272","article-title":"Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas","volume":"89","author":"Pinyol","year":"1997","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.hoc.2020.06.002_bib13","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","article-title":"Update on mantle cell lymphoma","volume":"132","author":"Maddocks","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2020.06.002_bib14","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"Supplement_1","key":"10.1016\/j.hoc.2020.06.002_bib15","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1182\/blood-2019-128632","article-title":"Short time to treatment is associated with inferior survival in newly diagnosed patients with mantle cell lymphoma","volume":"134","author":"Epperla","year":"2019","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.hoc.2020.06.002_bib16","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1200\/JCO.2009.23.9731","article-title":"Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma","volume":"27","author":"Eve","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2020.06.002_bib17","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","article-title":"Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study","volume":"124","author":"Abrahamsson","year":"2014","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.hoc.2020.06.002_bib18","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1002\/cncr.30068","article-title":"Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma","volume":"122","author":"Cohen","year":"2016","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.002_bib19","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1093\/annonc\/mdx333","article-title":"Observation as the initial management strategy in patients with mantle cell lymphoma","volume":"28","author":"Abrisqueta","year":"2017","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2020.06.002_bib20","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1080\/10428194.2018.1455973","article-title":"Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma","volume":"59","author":"Calzada","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.002_bib21","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.3324\/haematol.2018.201350","article-title":"Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma","volume":"104","author":"Kumar","year":"2019","journal-title":"Haematologica"},{"issue":"Supplement_1","key":"10.1016\/j.hoc.2020.06.002_bib22","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1182\/blood-2019-128340","article-title":"40% of females with mantle cell lymphoma are managed with initial observation: results from the MCL biobank observational study","volume":"134","author":"McCulloch","year":"2019","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.hoc.2020.06.002_bib23","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.hoc.2020.06.002_bib24","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.002_bib25","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.14870","article-title":"Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies","volume":"179","author":"Rule","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.002_bib26","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/S2352-3026(18)30018-8","article-title":"Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial","volume":"5","author":"Jerkeman","year":"2018","journal-title":"Lancet Haematol"},{"issue":"13","key":"10.1016\/j.hoc.2020.06.002_bib27","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.hoc.2020.06.002_bib28","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2018-11-886457","article-title":"A\u00a0phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma","volume":"133","author":"Martin","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2020.06.002_bib29","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1182\/blood.V87.8.3351.bloodjournal8783351","article-title":"p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas","volume":"87","author":"Hernandez","year":"1996","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.hoc.2020.06.002_bib30","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.002_bib31","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood-2018-03-838136","article-title":"A\u00a0gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome","volume":"132","author":"Clot","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.002_bib32","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2020.06.002_bib33","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2014.57.6801","article-title":"Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT)","volume":"33","author":"Wagner","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.002_bib34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hon.2900060103","article-title":"Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation","volume":"6","author":"Shustik","year":"1988","journal-title":"Hematol Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2020.06.002_bib35","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199805213382104","article-title":"Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia","volume":"338","author":"Dighiero","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"9383","key":"10.1016\/j.hoc.2020.06.002_bib36","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"issue":"S2","key":"10.1016\/j.hoc.2020.06.002_bib37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/hon.7_2629","article-title":"Ibrutinib versus placebo in patients with asymptomatic, treatment-na\u00efve early stage CLL: primary endpoint results of the phase 3 double-blind randomized CLL12 trial","volume":"37","author":"Langerbeins","year":"2019","journal-title":"Hematol Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2020.06.002_bib38","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2016.70.7901","article-title":"New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies","volume":"35","author":"Scott","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.002_bib39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjh.15170","article-title":"Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN)","volume":"181","author":"Smith","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2020.06.002_bib40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.canep.2018.12.002","article-title":"Increase in survival for patients with mantle cell lymphoma in the era of novel agents in 1995-2013: findings from Texas and national SEER areas","volume":"58","author":"Fu","year":"2019","journal-title":"Cancer Epidemiol"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.002_bib41","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J"},{"issue":"Supplement_1","key":"10.1016\/j.hoc.2020.06.002_bib42","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood-2019-122191","article-title":"Efficacy and safety of ibrutinib in combination with rituximab as frontline treatment for indolent clinical forms of mantle cell lymphoma (MCL): preliminary results of Geltamo IMCL-2015 phase II trial","volume":"134","author":"Gine","year":"2019","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:14:12Z","timestamp":1760184852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858820300654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0889858820300654"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.06.002","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Watch and Wait in Mantle Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}